98%
921
2 minutes
20
Background: Globally, people who inject drugs are highly vulnerable to HIV transmission. Methadone maintenance treatment (MMT) programs are one of the most cost-effective mechanisms to substitute opioid use and improve the quality of life of patients. Since the coverage of MMT is still limited and even for those patients who are treated, improving their knowledge on HIV and maintaining healthy behaviors are key to maximizing the outcomes of HIV harm reduction programs. This study examined the knowledge on HIV, perceived risk and HIV testing among drug users accessing methadone maintenance services in three Vietnamese mountainous areas.
Methods: A cross-sectional study of 300 people enrolling for MMT services in three provinces in Vietnam was conducted. The factors associated with the knowledge, attitudes, and practices of respondents about HIV/AIDS were exploited using multivariable logistic model.
Results: Of the 300-people surveyed, 99% knew of HIV and 60.6% were identified as having good knowledge. While 75.2% identified that injecting drugs was a risk factor for HIV, 52.2% thought they were not at risk of HIV mainly as they did not share needles. 92.6% had undergone HIV testing with 17.4% being positive, a number which was significantly lower than Vietnam's national average for people who inject drugs. Age, ethnicity and education were associated with knowledge of HIV while ART treatment was linked to self-assessed HIV status.
Conclusions: This study sheds new light on the knowledge attitudes and practices of people who inject drugs, particularly males in mountainous areas of Vietnam regarding HIV prevention. Overall, knowledge was good with most conducting safe practices towards transmission. Enhanced education and targeting of minority groups could help in increasing the numbers receiving MMT and HIV services.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334422 | PMC |
http://dx.doi.org/10.1186/s13011-019-0191-8 | DOI Listing |
J Med Virol
September 2025
Department of Interdisciplinary Oncology, School of Medicine, Stanley S. Scott Cancer Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
Kaposi sarcoma (KS) remains a global health concern. In sub-Saharan Africa, where there is a high burden of HIV-1 infection, there is also a high prevalence of infection by the etiologic agent of KS, the KS-associated herpesvirus (KSHV). Despite the successes of antiretroviral treatment (ART), the burden of KS and other KSHV-associated malignancies among people living with HIV under ART remained high, stressing the need for a greater understanding of the immune response against KSHV infection.
View Article and Find Full Text PDFTransfusion
September 2025
Medical Affairs and Innovation, Canadian Blood Services, Ottawa, Ontario, Canada.
Introduction: Donors are deferred if they are on antiretroviral medications (ARV) as post-exposure or pre-exposure prophylaxis (PEP or PrEP) for human immunodeficiency virus (HIV). We assessed donor compliance by measuring ARV levels in selected anonymized donor samples collected from September 22, 2022 to December 31, 2024, almost all after the introduction of sexual risk behavior screening.
Methods: EDTA plasma samples collected at the time of donation (retention samples) were retrieved, frozen, and shipped for measurement of tenofovir and emtricitabine.
Transfusion
September 2025
Infectious Disease Consultant, North Potomac, Maryland, USA.
Background: The Transfusion-Transmissible Infections Monitoring System assesses trends in ~60% of the US blood supply. Donors with high-risk behaviors, including injection drug use, men having sex with other men, or exchanging sex for money/drugs were deferred for 12 months (12M) from 2016 to 2020 and 3 months (3M) from 2020 to 2023. Here we evaluate HIV, HBV, and HCV incidence and window-period residual risk (WPRR) in two ~3-year periods of 12M (2017-2020) and 3M (2020-2023) to identify any differences.
View Article and Find Full Text PDFCurr HIV Res
September 2025
Department of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing 400030, China.
HIV-associated lymphoma (HAL) is an aggressive malignancy directly linked to HIV infection and accounts for more than 30% of cancer-related deaths in people living with HIV (PLWH). HAL subtypes, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), primary effusion lymphoma (PEL), and plasmablastic lymphoma (PBL), exhibit five to ten times higher incidence rates and distinct molecular profiles compared to HIV-negative lympho-mas. Pathogenesis involves HIV-driven CD4+ T-cell depletion, chronic B-cell activation, and on-cogenic viral coinfection.
View Article and Find Full Text PDFCurr HIV Res
September 2025
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.
Newborns represent only 1% of the population. Yet, HIV vertical transmissions represent 10% of all new infections globally, even though antiretroviral therapy (ART) has been shown to reduce the risk of vertical transmission to less than 2%. While vaccines still represent the most efficient and cost-effective intervention to eradicate new infections, HIV immunogens that can effectively elicit broad-spectrum protection are still at least a decade away.
View Article and Find Full Text PDF